高级检索
当前位置: 首页 > 详情页

The improvement of M1 polarization in macrophages by glycopeptide derived from Ganoderma lucidum

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

机构: [1]The Affiliated Hospital of Chengde Medical College, Chengde, Hebei province 067000, China [2]Department of Pharmacology, School of Basic Medical Sciences, Peking University Health Science Center, Beijing 100191, China [3]Department of Dermatology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei province 050011, China
出处:
ISSN:

关键词: Macrophages Polarization Ganoderma lucidum polysaccharides Cytokines

摘要:
Ganoderma lucidum (Fr.) Karst (Ganodermataceae) is a medicinal mushroom that has been extensively used in China for centuries to promote longevity and improve vigor without significant adverse effects. There is continuous interest in the bioactive properties of G. lucidum in view of its newly developed popularity in other regions besides Asia, such as Europe. Glycopeptide derived from G. lucidum (Gl-PS) is one of the main effective components isolated from this mushroom. The Gl-PS has been demonstrated pleiotropic with many bioactivities including immunomodulatory and antitumor effects. Macrophages are important cells involved in innate and adaptive immunity. Classically activated macrophages (M1) and alternatively activated macrophages (M2), with their different roles, display distinct cytokine profiles: M1 preferentially produces TNF-alpha, IL-6, and IL-12; conversely, M2 generates more IL-10 and arginase. Gl-PS might have the potential to promote macrophage M1 polarization by lipopolysaccharide (LPS). In this study, LPS was used to induce the M1 polarization. It was shown that the level of the TNF-alpha, IL-6, and IL-12 were increased and the IL-10 and arginase I were decreased in the polarized M1 macrophages after application of Gl-PS compared to the control. The results indicated the potential of Gl-PS to promote M1 polarization vs M2, with the health beneficial understanding of the bioactivities of Gl-PS.

基金:
语种:
被引次数:
WOS:
PubmedID:
中科院分区:
出版当年[2017]版:
大类 | 3 区 医学
小类 | 3 区 免疫学
最新[2025]版:
大类 | 4 区 医学
小类 | 4 区 免疫学
JCR分区:
出版当年[2017]版:
Q3 IMMUNOLOGY
最新[2024]版:
Q2 IMMUNOLOGY

影响因子: 最新[2024版] 最新五年平均 出版当年[2017版] 出版当年五年平均 出版前一年[2016版] 出版后一年[2018版]

第一作者:
第一作者机构: [1]The Affiliated Hospital of Chengde Medical College, Chengde, Hebei province 067000, China
通讯作者:
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:42329 今日访问量:0 总访问量:1365 更新日期:2025-08-01 建议使用谷歌、火狐浏览器 常见问题

技术支持:重庆聚合科技有限公司 地址:河北省石家庄市健康路12号